Peroxisome Proliferator Activated Receptors: From Basic Science to Clinical Applications

ISBN-13: 9781461354277 / Angielski / Miękka / 2012 / 172 str.

J. -C Fruchart; Antonio M. Gotto Jr; Rodolfo Paoletti

Opis

Peroxisome Proliferator Activated Receptors (PPARs) attract great attention in light of the wide spectrum of genes of biological and medical relevance identified as under their control. As a consequence, our knowledge of the role of these receptors in physiology and pathology continues to grow at a fast pace and PPARs have become an interesting target for the treatment of many pathological conditions, including diabetes and atherosclerosis. This volume provides an authoritative view of the current clinical and scientific developments within this evolving area of study.

Spis treści

Preface. List of Contributors. Structure, Function, and Molecular Mechanisms of PPAR Action. 1. Peroxisome Proliferator Activated Receptor Alpha Coordinates Intermediary Metabolism During Fasting; S. Kersten, et al. 2. Design, Structure, and Function of Novel PPAR Ligands; T.M. Willson, et al. 3. Functions of PPAR Gamma in Macrophages and Atherosclerosis; A. Chawla, et al. Inflammation and Atherosclerosis. 4. PPARs and Atherogenesis: Mediators or Modulators of the Inflammatory Response in the Vessel Wall? N. Marx. 5. Role of PPARs in Inflammation, Atherosclerosis, and Thrombosis; A. Pilon, et al. 6. Effects of Thiazolidinediones on Vascular Reactivity and Endothelial Dysfunction; E.S. Horton, et al. PPARgamma and alpha as Therapeutic Targets in Diabetes. 7. Activation of Human PPAR Subtypes by Pioglitazone; H. Kimura, et al. 8. PPARgamma Mechanism of Action Studies; S. Kliewer. Animal Models to Study PPAR Functions. 9. The Role of PPARalpha in Fatty Acid Metabolism and Hepatocarcinogenesis: Studies with PPARalpha-Null Mice; F.J. Gonzalez. PPARalpha: From Basic Science to Clinical Applications. 10. PPARalpha, Lipoprotein Metabolism, Metabolic Disease, and Atherosclerosis; J.-C. Fruchart, et al. 11. PPARalpha and Atherosclerosis; J. Plutzky. 12. Regulation of CD36 by PPARgamma: Pro- or Anti-atherogenic? M. Febbraio, et al. Lipid and Lipoprotein Metabolism and Atherosclerosis. 13. Anti-inflammatory Properties of HighDensity Lipoproteins; P. Barter, et al. The Importance of Raising HDL: From PPARalpha to Clinical Implications. 14. The Low-HDL Syndrome: Epidemiology and Pathophysiology; G. Franceschini, et al. 15. Diabetes: A Growing CHD Epidemic; A. Hamsten, G. Steiner. Adipose Tissue, Obesity, and Diabetes. 16. Influence of PPARs on Muscle Lipid Metabolism and Insulin Resistance; E.W. Kraegen, et al. 17. PPARgamma in Adipogenesis and Insulin Resistance; S.R. Farmer, et al. PPARdelta: Function and Biology. 18. Pharmacology of a Selective Peroxisome Proliferator-Activated Receptor delta Agonist, GW 501516, in Obese Dyslipidemic Primates; W. Oliver, et al. PPARgamma: From Basic Science to Clinical Applications. 19. PPARgamma: A Regulator of Growth and Differentiation; S.R. Farmer, et al. 20. Peroxisome Proliferator Activator Receptor Gamma Agonists Inhibit the Development of Atherosclerosis in Low Density Lipoprotein Receptor-Deficient Male Mice; A.C. Li, C.K. Glass. 21. Are Thiazolidinediones Superior to Standard Therapy in the Treatment of Type 2 Diabetes? M.-R. Taskinen. Clinical Studies with PPAR Ligands. 22. PPARgamma Ligands and Intestinal Inflammation; A. Flanigan, et al. 23. Inflammatory Mechanisms in Alzheimer's Disease: beta-Amyloidd-Stimulated Proinflammatory Responses Are Blocked by PPARgamma Agonists; G. Landreth, et al. Index.